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Abstract Beta-amyloid (Ab) and tau proteins, the pathological hallmarks of Alzheimer’s disease
(AD), are believed to spread through connected regions of the brain. Combining diffusion imaging
and positron emission tomography, we investigated associations between white matter
microstructure specifically in bundles connecting regions where Ab or tau accumulates and
pathology. We focused on free-water-corrected diffusion measures in the anterior cingulum,
posterior cingulum, and uncinate fasciculus in cognitively normal older adults at risk of sporadic AD
and presymptomatic mutation carriers of autosomal dominant AD. In Ab-positive or tau-positive
groups, lower tissue fractional anisotropy and higher mean diffusivity related to greater Ab and tau
burden in both cohorts. Associations were found in the posterior cingulum and uncinate fasciculus
in preclinical sporadic AD, and in the anterior and posterior cingulum in presymptomatic mutation
carriers. These results suggest that microstructural alterations accompany pathological
accumulation as early as the preclinical stage of both sporadic and autosomal dominant AD.
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Introduction
The progression of Alzheimer’s disease (AD) includes a long asymptomatic phase, during which
accumulating pathology is accompanied by various brain changes (Jack et al., 2013; Sperling et al.,
2011). Beta-amyloid (Ab) and tau proteins, the pathological hallmarks of the disease
(Duyckaerts et al., 2009), start to accumulate decades before signs of cognitive impairment
(Bateman et al., 2012; Jansen et al., 2015). Positron emission tomography (PET) can image both
proteins in vivo (Johnson et al., 2016; Klunk et al., 2004; Schöll et al., 2016), and thus help in iden-
tifying the earliest brain changes associated with such pathologies. Ab- and tau-PET tracer accumu-
late in distinct patterns of deposition that follows canonical brain networks/organization. Ab
develops a widespread pattern of deposition that recapitulates a default mode network-like pattern,
accumulating early in the frontal and parietal lobes (Mattsson et al., 2019; Villeneuve et al., 2015).
Tau accumulates in a more localized pattern that can start in the locus coeruleus before being
detectable by tau-PET scans, followed by the medial temporal lobe in the preclinical phase of the
disease, and spreading to the lateral temporal lobe and the rest of the brain in late stages
(Braak and Braak, 1991; Braak et al., 2011). A prominent view is that pathology accumulates in
functionally and/or structurally connected regions (Franzmeier et al., 2019; Seeley et al., 2009;
Sepulcre et al., 2017; Vogel et al., 2020). Many studies have highlighted associations between Ab-
and tau-PET and brain functional activity early in the course of the disease (Berron et al., 2020;
Jones et al., 2017; Mormino et al., 2011; Sepulcre et al., 2017). However, relations between
pathology and white matter (WM) microstructure, as assessed by diffusion magnetic resonance
imaging (MRI), remain elusive in preclinical AD. While WM degeneration is clearly apparent in the
late symptomatic stages, how WM microstructure is affected early on in the disease process is less
clear (Sachdev et al., 2013). Whole-brain diffusion MRI tractograms can represent the brain’s WM
architecture, but these are difficult to reconstruct because of extensive crossing of WM fibers and
the complexity of tracking algorithms (Rheault et al., 2020). Recent advances in modeling and avail-
able algorithms have facilitated robust extraction of WM bundles with automated methods, thereby
allowing their more precise investigation. As well, more specific measures have become available for
analysis of WM (Dyrby et al., 2014). In particular, free-water (FW)-corrected diffusion tensor meas-
ures may offer better estimates of WM microstructure, yielding tissue-based fractional anisotropy
and diffusivities after removing the FW contribution to each voxel (Pasternak et al., 2009).
We investigated diffusion-based measures of WM microstructure in bundles that connect cortical
regions vulnerable to Ab and tau deposition. We hypothesized that such bundles would show lower
fractional anisotropy and higher diffusivity with more pathology as proxy of WM degeneration. We
sought to expand upon the few studies linking preclinical AD pathology and WM microstructure and
focused on bundles (defined a priori) connecting brain regions targeted early by AD pathology,
notably the cingulum bundle (Jacobs et al., 2018). The latter is a large association bundle under the
cingulate gyri that connects anterior to posterior cingulate regions and curves further into the para-
hippocampal gyri of the temporal lobe. This bundle is typically affected in symptomatic AD demen-
tia (Bubb et al., 2018; Jacobs et al., 2018; Kantarci et al., 2017; Roy et al., 2020; Wen et al.,
2019), and given its location, could be preferentially affected by Ab, particularly in its anterior seg-
ment. Also of interest is the uncinate fasciculus, reported to be affected at the stage of mild cogni-
tive impairment (Mito et al., 2018; Roy et al., 2020). This bundle connects parts of the limbic
system, such as the hippocampus and amygdala, with the orbitofrontal cortex (Von Der Heide
et al., 2013), brain regions thought to be key regions for tau and Ab propagation, respectively
(van der Kant et al., 2020). Our objective was to investigate associations between the microstruc-
ture in those bundles of interest and AD pathology in two cohorts of cognitively normal individuals
at risk of AD, older adults at increased risk of sporadic AD and presymptomatic mutation carriers of
autosomal dominant AD (ADAD).




Using state-of-the-art methods in diffusion MRI modeling, tractography, and tractometry, we aimed
to better understand the associations between WM microstructure of key bundles in preclinical AD
and deposition of Ab and tau as measured by PET. We reasoned that the preclinical stage of AD
should be the ideal point at which to study these questions, given that this is a period during which
AD pathology is spreading but overall brain structure and function remain largely preserved. We
therefore studied the preclinical stage of both late-onset sporadic AD and ADAD. Sporadic AD is
the most common form of dementia, is multifactorial, and occurs most often in late life. ADAD is the
rarer form of AD, caused by fully penetrant genetic mutations in PSEN1, PSEN2, or APP, that leads
to Ab accumulation up to 20 years prior to symptom onset (Bateman et al., 2012) and to onset of
cognitive symptoms often in the 40s and early 50s. ADAD is considered a ‘purer’ form of preclinical
AD since most mutation carriers do not exhibit age-associated co-pathologies. We studied a subset
of 126 asymptomatic individuals at high risk of sporadic AD from the PRe-symptomatic EValuation of
Experimental or Novel Treatments for AD (PREVENT-AD) cohort (Breitner et al., 2016) and 81
ADAD presymptomatic mutation carriers from the Dominantly Inherited Alzheimer’s Network (DIAN)
cohort (Morris et al., 2012). PREVENT-AD enrolls cognitively normal older adults at risk of sporadic
AD given their parental or multiple-sibling family history of the disease. At the time of study, partici-
pants were on average 67.3 years of age, predominantly female, and highly educated (Table 1).
Based on a threshold established previously using global cortical Ab burden (McSweeney et al.,
2020), 19% of the participants were considered Ab-positive. We also considered the same propor-
tion of participants with the highest entorhinal tau uptake to be tau-positive. DIAN enrolls adults
from families with ADAD. Our focus was on presymptomatic mutation carriers, but analyses were
also conducted in mutation non-carriers in order to rule out false-positive associations that could be
due to off-target binding properties of the PET tracer. Mutation carriers were on average 34.5 years
of age, while non-carriers were slightly older. Both groups had more than 50% female and were
highly educated. For the DIAN cohort, we had access to Ab-PET only, with 43% of the mutation car-
riers and none of the non-carriers classified as Ab-positive (Su et al., 2013).
Table 1. Demographics.
PREVENT-AD
(n = 126) DIAN mutation carriers (n = 81) DIAN mutation non-carriers (n = 96)
Age (years) 67.3 ± 4.8 (68–83) 34.5 ± 9.9 (18–61) 39.3 ± 11.7 (19–69)
Sex F:M (%F) 94:32 (75%) 42:39 (52%) 56:40 (58%)
APOE4 carriers (%) 50 (40%) 24 (30%) 26 (27%)
Education (years) 15.2 ± 3.3 (7–24) 15.2 ± 3.0 (10–24) 15.1 ± 2.7 (10–26)
Handedness (n, % right-handed) 114 (90%) 69 (85%) 82 (85%)
Systolic blood pressure 129.0 ± 13.8 (100–164) 122.5 ± 10.2 (95–155) 123.5 ± 17.1 (90–190)
Diastolic blood pressure 74.0 ± 8.1 (60–96) 75.2 ± 8.8 (55–104) 77.1 ± 10.1 (60–110)
Global Ab SUVR* 1.3 ± 0.3 (1.0–2.8) 1.6 ± 0.7 (0.8–3.7) 1.0 ± 0.1 (0.9–1.3)
Ab-positive (%) 24 (19%) 35 (43%) 0 (0%)
Entorhinal tau SUVR 1.1 ± 0.1 (0.7–1.6) NA NA
Mini-Mental State Examination 28.8 ± 1.2 (24–30) 29.0 ± 1.3 (24–30) 29.2 ± 1.2 (25–30)
Estimated years to symptom onset†  5.7 ± 7.6 ( 20.8 to 16.8)  13.6 ± 8.3 ( 31.5 to 11.8)  7.4 ± 12.5 ( 28.8 to 21.4)
Values represent Mean ± SD (range). Participants with at least one e4 allele were considered APOE4 positive. The Mini-Mental State Evaluation was admin-
istered at the same time as PET.
* Note that NAV4694 was used in PREVENT-AD and PIB was used in DIAN.
† Estimated years to symptom onset was calculated as the parent’s age at dementia onset minus the age of the participant; four missing values in PRE-
VENT-AD.
Ab: beta-amyloid; APOE: apolipoprotein E; SUVR: standardized uptake value ratio; PET: positron emission tomography.
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Methodology overview
We extracted FW-corrected diffusion tensor measures in bundles of interest. We reconstructed each
individual’s whole-brain tractogram using high angular resolution diffusion imaging and fiber orienta-
tion distribution functions (fODFs), and employed automated tools to isolate the anterior cingulum,
the posterior cingulum, and the uncinate fasciculus (Garyfallidis et al., 2018; Rheault, 2020;
Wassermann et al., 2016). Tractometry then generated bundle-specific quantification of five WM
properties (Cousineau et al., 2017; Rheault et al., 2017). These were tissue fractional anisotropy
(FAT), mean diffusivity (MDT), axial diffusivity (ADT), and radial diffusivity (RDT). In each, ‘T’ represents
tissue in these FW-corrected diffusion tensor measures. We also report the FW index, which is
thought to reflect a measure of neuroinflammation (Pasternak et al., 2009). To investigate the rela-
tionships with AD pathology, we focused on typical measures of Ab- and tau-PET, which is a global
cortical Ab burden (in PREVENT-AD and DIAN) and entorhinal tau tracer uptake (in PREVENT-AD
only).
We first evaluated the partial correlations between WM microstructure and pathology at the
whole group level, controlling for age, sex, and bundle volume. We then repeated these analyses
while restricting them to participants with (Ab-positive or tau-positive) and without (Ab-negative or
tau-negative) pathology. The analysis conducted in Ab-positive or tau-positive groups was especially
important for the PREVENT-AD cohort since participants free from pathology might never develop
AD. In complementary analyses, to investigate whether the associations would be independent from
gray matter (GM) neurodegeneration, we further added GM volume in brain regions connected by
our bundles of interest as covariates in the regression models. Lastly, we evaluated whether similar
associations could be detected with typical diffusion tensor measures, that is, FA, MD, AD, and RD
(not corrected for FW).
An overview of the processing steps is shown in Figure 1 and can be summarized as follows: in
three a priori WM bundles of interest extracted in the left and right hemisphere from each partici-
pant’s tractogram, we evaluated associations between five related microstructure measures and AD
pathology measured with PET (global cortical Ab and entorhinal tau). We analyzed all five WM
microstructure measures to detect whether a consistent pattern of associations across measures
emerges rather than focusing on one given measure.
Associations in the uncinate fasciculus and posterior cingulum in
PREVENT-AD Ab-positive and tau-positive groups
In PREVENT-AD, at the level of the whole group, there were no associations between global cortical
Ab or entorhinal tau burden with any of the WM microstructure measures across the three bundles
of interest (Figure 2—source data 1, Figure 3—source data 1). Associations were detected only in
the participants considered as Ab-positive or tau-positive. In the Ab-positive group, controlling for
age, sex, and bundle volume, lower FAT, higher MDT, and higher RDT in the left posterior cingulum
and in the uncinate fasciculus were related to greater cortical Ab burden (Figure 2, Figure 2—
source data 1). Similar associations were present in the right uncinate fasciculus at trend level
(p=0.06 for FAT, MDT, and RDT). Further, in the posterior cingulum, tau-positive participants dis-
played the same pattern of associations aforementioned; in this group, lower FAT, higher MDT, and
higher RDT in the left posterior cingulum related to greater entorhinal tau-PET tracer binding (Fig-
ure 3, Figure 3—source data 1). Associations in the right posterior cingulum in tau-positive partici-
pants were trend level (p=0.06 for FAT, MDT, and RDT).
In the anterior cingulum, there were no associations between WM measures and pathology in
either Ab-positive or tau-positive participants (Figures 2D–3D). No association was found in the Ab-
and tau-negative groups.
Associations in anterior and posterior cingulum in DIAN mutation
carriers
In DIAN mutation carriers, associations were found at the group level between global Ab burden
and WM microstructure in the anterior cingulum, following the same pattern of associations as in
PREVENT-AD. As such, lower FAT, higher MDT, and higher RDT related to greater cortical Ab across
all mutation carriers (partial R =  0.27 for FAT and 0.28 for MDT and RDT, p=0.02; Figure 4—source
data 1), but associations were higher when restricted to the Ab-positive participants (Figure 4A–D).
Pichet Binette et al. eLife 2021;10:e62929. DOI: https://doi.org/10.7554/eLife.62929 4 of 28
Research article Neuroscience
Associations in Ab-positive participants were also found in the right posterior cingulum (Figure 4B–
E). Focusing only on the Ab-negative group, microstructure measures in the posterior cingulum were
associated with global cortical Ab in the same directions as in the Ab-positive group (partial
R =  0.31 for FAT and 0.31 for MDT and RDT, p=0.01). Of note, we did not find any associations
between bundle microstructure and pathology in mutation non-carriers.
Effect of GM atrophy on microstructure-pathology associations
We further wanted to evaluate whether significant associations between bundle microstructure and
pathology in Ab-positive or tau-positive participants were affected by GM atrophy. To do so, we
added GM volume specifically in brain regions connected by the bundle of interest as an additional
covariate. Partial correlations were thus controlled for age, sex, bundle volume, and GM volume.
GM volume of the following regions were considered: the anterior and posterior cingulate cortex for
the anterior cingulum, the precuneus and the parahippocampal gyrus for the posterior cingulum,
and the medial orbitofrontal cortex and the parahippocampal gyrus for the uncinate fasciculus. In
both PREVENT-AD and DIAN, further adjusting for GM volume did not change the significance of
the microstructure measures in neither the anterior cingulum nor the uncinate fasciculus. The only
Figure 1. Overview of the processing steps. PREVENT-AD and DIAN participants were processed following the same pipeline. Whole-brain tractogram
was reconstructed using the TractoFlow Atlas-Based Segmentation pipeline, and automated bundle extraction tools were used to extract the bundles
of interest in each hemisphere. Free-water-corrected tensor measures were calculated for each bundle. Associations between white matter
microstructure and global Ab and entorhinal tau PET were then investigated. Ab: beta-amyloid; PET: positron emission tomography; SUVR:
standardized uptake value ratio.
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bundle where atrophy changed the original associations was the posterior cingulum, with GM vol-
ume of the precuneus as a covariate. In both PREVENT-AD and DIAN, in models including volume of
the precuneus, microstructure properties were no longer related to pathology. When volume of the
parahippocampal gyrus was a covariate in the models of the posterior cingulum, microstructure
associations were unchanged compared to the initial analyses, with the exception of the ones with
Ab burden in PREVENT-AD (the contribution of diffusion measures became marginal, changing from
p=0.05 to p=0.06). In complementary analyses, we evaluated whether GM volume related to Ab-
and tau-PET controlling for age and sex. The main significant associations were in the right precu-
neus or posterior cingulate in PREVENT-AD and in the right posterior cingulate in DIAN (Table 2).
Figure 2. Associations between diffusion measures and Ab burden in Ab-positive PREVENT-AD participants. (A–C) Bivariate associations between FAT
and global cortical Ab in each bundle in the left hemisphere to show examples of raw values in PREVENT-AD. Data are represented for the full sample,
with Ab-positive in orange (our group of interest) and Ab-negative in gray. (D–F) Partial correlations between diffusion measures (average diffusion
measure in the bundle) and global cortical Ab-PET controlling for age, sex, and bundle volume (divided by total intracranial volume) were performed in
PREVENT Ab-positive participants. Partial correlation coefficient for each diffusion measure in the right and left bundles is reported as bar graphs. Black
asterisks highlight that associations are significant in both hemispheres, otherwise the color of the symbol matches the hemisphere where the
association is significant. *p=0.05; ** 0.05 > p > 0.001; +p=0.06. See also Figure 2—source data 1. Ab: beta-amyloid; FAT: tissue fractional anisotropy;
MDT: tissue mean diffusivity; ADT: tissue axial diffusivity; RDT: tissue radial diffusivity; FW: free-water index; PET: positron emission tomography.
The online version of this article includes the following source data for figure 2:
Source data 1. Associations between microstructure and beta-amyloid–positron emission tomography (Ab-PET) in PREVENT-AD.
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Importance of advanced FW measures to these results
To evaluate the sensitivity of FW-corrected measures over the typical tensor measures, we tested
whether similar associations with pathology exist with FA, MD, AD, and RD (i.e., not corrected for
FW). Except for FA, which gave similar results to FAT, MD, RD, and AD were not associated with
pathology in any bundle (Table 3), suggesting that FW-corrected measures capture subtle WM
microstructure alterations not always detectable with more classical diffusion tensor imaging
(DTI) measures.
Figure 3. Associations between diffusion measures and entorhinal tau burden in tau-positive PREVENT-AD participants. (A–C) Bivariate associations
between FAT and entorhinal tau in each bundle in the left hemisphere to show examples of raw values in PREVENT-AD. Data are represented for the
full sample, with tau-positive in blue (our group of interest) and tau-negative in gray. (D–F) Partial correlations between diffusion measures (average
diffusion measure in the bundle) and entorhinal tau-PET controlling for age, sex, and bundle volume (divided by total intracranial volume) were
performed in PREVENT tau-positive participants. Partial correlation coefficient for each diffusion measure in the right and left bundles is reported as bar
graphs. The color of the symbol on the bar graphs matches the hemisphere where the association is significant. *p=0.05; ** 0.05 > p > 0.001;
+p=0.06. See also Figure 3—source data 1. FAT: tissue fractional anisotropy; MDT: tissue mean diffusivity; ADT: tissue axial diffusivity; RDT: tissue radial
diffusivity; FW: free-water index; PET: positron emission tomography.
The online version of this article includes the following source data for figure 3:
Source data 1. Associations between microstructure and tau-positron emission tomography (tau-PET) in PREVENT-AD.
Pichet Binette et al. eLife 2021;10:e62929. DOI: https://doi.org/10.7554/eLife.62929 7 of 28
Research article Neuroscience
Discussion
The notion that AD pathology accumulates in connected regions in the brain has foundations in
rodent models (Ahmed et al., 2014; Jucker and Walker, 2018; Palop and Mucke, 2010), and it is
gaining credence in human neuroimaging studies. It is striking how pathology deposit in structurally
or functionally connected regions (Franzmeier et al., 2020; Seeley et al., 2009; Sepulcre et al.,
2016; Vogel et al., 2020). However, there is limited evidence on how WM microstructure in bundles
linking those key pathology regions is affected in the early phases of AD. Combining Ab- and tau-
PET with recent advanced diffusion imaging analyses, we investigated WM microstructure in bundles
(selected a priori) that connect key AD brain regions with Ab and tau deposition. Our aim here was
Figure 4. Associations between diffusion measures and Ab burden in Ab-positive DIAN mutation carriers. (A–C) Bivariate associations between FAT and
global cortical Ab in each bundle in the left hemisphere to show examples of raw values in DIAN. Data are represented for the full sample, with Ab-
positive in red (our group of interest) and Ab-negative in gray. (D–F) Partial correlations between diffusion measures (average diffusion measure in the
bundle) and global cortical Ab-PET controlling for age, sex, and bundle volume (divided by total intracranial volume) were performed in DIAN Ab-
positive participants. Partial correlation coefficient for each diffusion measure in the right and left bundles is reported as bar graphs. Black asterisks
highlight that associations are significant in both hemispheres, otherwise the color of the symbol matches the hemisphere where the association is
significant *p=0.05; ** 0.05 > p > 0.001. See also Figure 4—source data 1. Ab: beta-amyloid; FAT: tissue fractional anisotropy; MDT: tissue mean
diffusivity; ADT: tissue axial diffusivity; RDT: tissue radial diffusivity; FW: free-water index; PET: positron emission tomography.
The online version of this article includes the following source data for figure 4:
Source data 1. Associations between microstructure and beta-amyloid–positron emission tomography (Ab-PET) in DIAN.
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not to test the spreading hypothesis per se, but, assuming that this hypothesis is correct, to focus on
local effects of microstructure alterations and the presence of AD pathology in the preclinical stage
of the disease. We investigated diffusion–PET associations in a cohort of asymptomatic older adults
at risk of AD dementia due to their family history of sporadic AD and presymptomatic ADAD muta-
tion carriers. In both cohorts, we found lower FAT, higher MDT, and higher RDT were related to
greater pathology. In PREVENT-AD, associations were found in the uncinate fasciculus and the pos-
terior cingulum, whereas in DIAN associations were found in the anterior and posterior segments of
the cingulum. Furthermore, in the PREVENT-AD the associations were restricted to participants with
significant AD pathology. These results suggest that significant levels of Ab- and tau-PET tracer bind-
ing are associated with WM neurodegeneration both in the preclinical phase of sporadic AD and
ADAD.
Our ‘bundle-specific’ approach through tractography and tractometry suggests topographical
relationships between pathology and WM microstructural alterations in the early stage of AD and
complements the typical approach of voxel-wise analyses (Harrison et al., 2020; Zhang et al.,
2019). Using more precise tissue measures with FW corrected as opposed to classical diffusion ten-
sor measures strengthened our findings, further highlighting the relevance of novel methods. Most
of the models proposing a cascade of events over the course of AD have not included WM altera-
tions (Iturria-Medina et al., 2016; Jack et al., 2013). One exception being a recent model in ADAD
that included diffusivity, with higher MD being detectable 5–10 years prior to symptom onset
(Araque Caballero et al., 2018). Although the current study design precludes us from staging when
microstructure starts to change, our findings suggest that WM degeneration already occurs with
early pathology accumulation prior to symptom onset both in the sporadic and the
autosomal dominant forms of AD.
The observed associations follow the classical pattern of degeneration that is characterized by
lower anisotropy and higher diffusivity, representing loss of coherence in the WM microstructure
with AD progression (Badea et al., 2016; Caso et al., 2016; Sexton et al., 2011). This pattern of
WM degeneration develops invariably along the AD spectrum (Amlien and Fjell, 2014;
Pereira et al., 2019), with changes often becoming detectable only in the mild cognitive impairment
and dementia stages (Mito et al., 2018; Song et al., 2018; Wang et al., 2019; Wen et al., 2019),
and rarely in Ab-positive cognitively normal participants (Rieckmann et al., 2016; Vipin et al.,
2019). Our results further emphasize that in presymptomatic populations associations start to be







Rpartial p-value Rpartial p-value Rpartial p-value
Left hemisphere
Anterior cingulate  0.239 0.271 0.032 0.891  0.207 0.248
Posterior cingulate  0.116 0.598  0.156 0.5  0.252 0.156
Precuneus  0.265 0.221  0.439 0.047  0.307 0.082
Parahippocampal gyrus 0.114 0.605  0.073 0.753 0.079 0.661
Medial orbitofrontal cortex  0.468 0.024  0.197 0.392  0.174 0.334
Right hemisphere
Anterior cingulate  0.335 0.118  0.085 0.713  0.133 0.461
Posterior cingulate  0.342 0.111  0.546 0.01  0.352 0.045
Precuneus  0.468 0.024  0.491 0.024  0.287 0.105
Parahippocampal gyrus 0.014 0.948  0.213 0.355 0.16 0.373
Medial orbitofrontal cortex  0.358 0.093  0.237 0.301 0.014 0.94
Rpartial and p-values from regression models investigating associations between gray matter volume (divided by total intracranial volume; independent vari-
able) and pathology (dependent variable) in Ab-positive or tau-positive participants in PREVENT-AD and DIAN. Models included age and sex as
covariates.
Ab: beta-amyloid; PET: positron emission tomography.
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Anterior cingulum Posterior cingulum Uncinate fasciculus
Rpartial p-value Rpartial p-value Rpartial p-value
Left hemisphere
FA  0.128 0.571  0.429 0.046  0.526 0.012
MD 0.022 0.923 0.18 0.424 0.32 0.147
AD  0.106 0.637  0.315 0.153  0.305 0.168
RD 0.081 0.721 0.305 0.168 0.448 0.037
Right hemisphere
FA  0.021 0.927  0.3 0.175  0.566 0.006
MD  0.048 0.831 0.131 0.56 0.078 0.729
AD  0.067 0.766  0.102 0.651  0.381 0.08
RD  0.019 0.931 0.221 0.322 0.344 0.116
Tau-positive
Anterior cingulum Posterior cingulum Uncinate fasciculus
Rpartial p-value Rpartial p-value Rpartial p-value
Left hemisphere
FA  0.465 0.039  0.523 0.018 0.108 0.65
MD 0.511 0.021 0.396 0.084 0.054 0.821
AD 0.112 0.639 0.082 0.731 0.206 0.384
RD 0.546 0.013 0.465 0.039  0.014 0.953
Right hemisphere
FA  0.461 0.041  0.487 0.029  0.399 0.081
MD 0.416 0.068 0.372 0.106 0.211 0.372
AD 0.012 0.959 0.157 0.508  0.011 0.965
RD 0.495 0.027 0.444 0.05 0.311 0.182
DIAN
Ab-positive
Anterior cingulum Posterior cingulum Uncinate fasciculus
Rpartial p-value Rpartial p-value Rpartial p-value
Left hemisphere
FA  0.373 0.035  0.192 0.293  0.031 0.868
MD 0.15 0.413  0.051 0.783  0.015 0.935
AD  0.196 0.283  0.226 0.213  0.067 0.716
RD 0.318 0.076 0.049 0.79 0.021 0.91
Right hemisphere
FA  0.452 0.009  0.4 0.023  0.35 0.049
MD 0.122 0.505  0.002 0.991 0.108 0.558
AD  0.239 0.188  0.219 0.229  0.098 0.595
RD 0.335 0.061 0.146 0.426 0.209 0.251
Rpartial and p-values from regression models investigating associations between each tensor measure (average diffu-
sion measure in the bundle; independent variable) and pathology (dependent variable) in PREVENT-AD Ab-positive
or tau-positive participants and DIAN Ab-positive participants. Models included age, sex, bundle volume (divided by
total intracranial volume) as covariates.
Ab: beta-amyloid; FA: fractional anisotropy; MD: mean diffusivity; AD: axial diffusivity; RD: radial
diffusivity; PET: positron emission tomography.
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detectable in individuals with high amount of pathology. In effect, most of the microstructure-pathol-
ogy associations were restricted to the Ab-positive or tau-positive participants. We should note that
in the asymptomatic stage there is also evidence of WM alterations opposing the typical degenera-
tion pattern, suggesting a possible biphasic relationship over the course of the disease
(Fortea et al., 2010; Montal et al., 2018; Wearn et al., 2020). For instance, hypertrophy, glial acti-
vation, neuronal or glial swelling have been attributed higher anisotropy and lower diffusivity in the
asymptomatic phase (Fortea et al., 2010; Montal et al., 2018). The biomarker status (i.e., Ab-posi-
tive or negative) might be important to disentangle such early processes (Dong et al., 2020;
Racine et al., 2014). Not dichotomizing by pathology status might obscure some associations in the
early disease stages, as shown here.
The bundle that was consistently affected in participants with high pathology in both cohorts was
the posterior cingulum, a key bundle in AD (Agosta et al., 2011; Caso et al., 2016; Zhuang et al.,
2012). The posterior cingulum is certainly altered in the symptomatic stage, and diffusivity in this
bundle has also shown to be related to tau accumulation in preclinical individuals (Jacobs et al.,
2018). In the PREVENT-AD cohort, the posterior segment of the bundle was the only region where
tau-positive participants presented WM degeneration with greater entorhinal tau. In DIAN, although
we did not have tau-PET, we hypothesize that the associations found in Ab-positive in the posterior
cingulum would be present with tau since mutation carriers harbor elevated tau binding in the precu-
neus (Gordon et al., 2019). In an attempt to explore whether associations were independent of
atrophy in brain regions connected the bundles of interest, we also controlled for GM volume in
such regions. In both cohorts, the precuneus is the only region where, when added as a covariate,
microstructure was no longer related to pathology. Such finding might suggest that this critical
region in AD pathophysiology might already be further along the degeneration process, with white
and GM being affected. Our results both in preclinical sporadic and ADAD corroborate the idea that
the precuneus/posterior cingulum, more largely part of the posterior default mode network or pos-
terior-medial system, is a critical area in the cascading events of AD (Berron et al., 2020;
Jones et al., 2016).
In DIAN, the other bundle where Ab and WM measures were related was the anterior cingulum,
another bundle connecting key regions where Ab accumulates. In line with these results, similar asso-
ciations have been found in DIAN using CSF Ab (Finsterwalder et al., 2020). On the other hand, in
PREVENT-AD, the strongest associations with Ab were detected in the uncinate fasciculus. This bun-
dle has an interesting anatomy, connecting regions at the intersection of both Ab (frontal lobe) and
tau (temporal lobe) deposition patterns in sporadic AD. We speculate that the particular localization
of the uncinate fasciculus with regards to Ab and tau deposition might confer early vulnerability to
pathological insults. Further, the orbitofrontal cortex is not only a region where Ab pathology accu-
mulates early but is also a highly plastic late-developing region, typically affected in aging
(Fjell et al., 2014; Pichet Binette et al., 2020). This might in part explain why the uncinate fasciculus
is preferentially affected in preclinical sporadic AD compared to the younger mutation carriers of
ADAD.
The direct investigation of WM fiber bundles and their microstructure was possible due to recent
advances in diffusion imaging modeling, tractography, bundle extraction, and tractometry quantifi-
cation. However, there are several limitations to these techniques and to our study. First, there are
no common standards (yet) to extract predefined bundles from tractograms, and bundles with high
curvature are more challenging to extract. To mitigate this challenge, we mostly relied on algorithms
that use priors to help generate fuller bundles. We also used automated algorithms to increase
reproducibility and performed rigorous visual inspection to make sure all algorithms yielded compa-
rable bundles. The diffusion sequence, similar in both cohorts, relied on only one b-value, and future
acquisitions with multiple b-values could further improve capturing fine-grained changes
(Pines et al., 2020). We should also note that the PREVENT-AD cohort does not present highly ele-
vated levels of tau, hence the deliberate choice of focusing on the proportion of participants with
the highest levels rather than applying a definite cut-off. The sample size might not be huge, but we
replicate all main findings in our two groups of interest. Both cohorts are also followed over time on
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cognition and imaging, so future longitudinal studies can help clarify the sequence of events
between pathology and WM changes in the preclinical and early symptomatic stages.
Overall, we used state-of-the-art analytical techniques to study associations between WM micro-
structure and Ab- and tau-PET in key bundles affected in AD in the PREVENT-AD cohort of cogni-
tively normal older adults whose strong family history of AD suggests an increased risk of
subsequent dementia (Cupples et al., 2004; Devi et al., 2000) and in presymptomatic mutation car-
riers from the DIAN cohort. We highlighted the vulnerability of WM bundles to early presence of Ab
and tau proteins. More generally, the topography of our results aligns with the concept of retrogen-
esis, postulating that late-myelinated fibers, from temporal and neocortical regions, are affected first
in the disease course and less resistant to neurodegeneration (Alves et al., 2015; Bartzokis, 2004;
Bartzokis, 2011). As more studies highlight that WM changes might precede changes in GM
(Caso et al., 2016; Sachdev et al., 2013), further investigations of WM microstructure in the early




We studied cognitively unimpaired participants at risk of sporadic AD dementia from the PREVENT-
AD study. PREVENT-AD is a longitudinal study that started in 2012 (Breitner et al., 2016) and
enrolled 386 participants. Inclusion criteria were as follows: (1) having intact cognition; (2) having a
parent or two siblings diagnosed with AD-like dementia, and therefore being at increased risk of
sporadic AD; (3) being above 60 years of age, or between 55 and 59 if fewer than 15 years from
their affected family member’s age at symptom onset; and (4) being free of major neurological and
psychiatric diseases. Overall participants presented low vascular risk factors and about 28% took
anti-hypertensive drugs (Köbe et al., 2020). Intact cognition was based on the Montreal Cognitive
Assessment, a Clinical Dementia Rating of 0, and a standardized neuropsychological evaluation
using the Repeatable Battery for the Assessment of Neuropsychological Status (Randolph et al.,
1998). The cognitive status of individuals with questionable neuropsychological status was reviewed
in consensus meetings of neuropsychologists (including SV) and/or psychiatrists. Annual visits include
neuropsychological testing and an MRI session. Since 2017, Ab and tau PET scans were integrated
to the study protocol for interested participants. The present study includes participants who had
structural and diffusion-weighted MRI and who underwent PET, for a total of 126 participants. All
participants included in the current study were cognitively normal at the time they underwent neuro-
imaging. All underwent diffusion MRI an average of 1.1 ± 0.8 years prior to PET imaging (one com-
pleted MRI 5 years prior to PET, but results were unchanged when this participant was removed
from analyses).
DIAN
The DIAN study group enrolls individuals over 18 years old with a family history of ADAD. We had
access to the DIAN data-freeze 11 of November 2016, from which we selected participants who
were cognitively normal as evidenced by Clinical Dementia Rating (Morris, 1993) of 0, and who
underwent both Ab-PET and diffusion MRI. Out of the 302 participants with a baseline visit with
imaging, 201 underwent diffusion MRI with 64 directions (we excluded 12 participants who only had
diffusion MRI with 32 directions), and from those, 177 had Ab-PET and all demographics available.
The final sample thus comprised 81 mutation carriers (49 PSEN1 mutation carriers, 15 PSEN2 muta-
tion carriers, and 17 APP mutation carriers) and 96 mutation non-carriers. Less than 1% of mutation
carriers and 14% of non-carriers were categorized as having hypertension.
Image acquisition
Magnetic resonance imaging
PREVENT-AD is a single-site study. All MRI images were acquired on a Magnetom Tim Trio 3 Tesla
(Siemens) scanner at the Douglas Mental Health University Institute prior to PET imaging. Structural
scans were acquired yearly, and thus we selected the closest scan prior to PET (average time
between PET and structural MRI: 8 ± 4 months). Diffusion-weighted MRI was not acquired every
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year, and again the diffusion scan closest to PET was chosen for analysis (average time between PET
and diffusion-weighted MRI: 1.1 ± 0.8 years). DIAN is a multisite study, and the imaging protocols
(MRI and PET) were unified across the different study sites. MRI was also acquired on Siemens 3T
scanners (BioGraph mMR PET-MR or Trio). All imaging data were selected from the baseline visit of
every participant.
In both studies, the T1-weighted structural image was acquired using a MPRAGE sequence similar
to the Alzheimer Disease Neuroimaging Initiative protocol (TR = 2300 ms; TE = 2.98 ms; FA = 9˚;
FoV = 256 mm; slice thickness = 1 mm; 160–170 slices). In both cohorts, diffusion-weighted MRI con-
sisted of one b0 image and 64 diffusion-weighted volumes acquired with a b-value of 1000 s/mm2.
The PREVENT-AD sequence parameters were the following: TR = 9300 ms, TE = 92 ms, FoV = 130
mm, 2 mm voxels. The DIAN sequence parameters were the following: TR = 11500 ms, T = 87 ms,
2.5 mm voxels.
Positron emission tomography
In PREVENT-AD, PET was performed using [18F]NAV4694 to assess Ab burden and flortaucipir ([18F]
AV1451) to assess tau deposition. PET scanning took place at the McConnell Brain Imaging Centre
at the Montreal Neurological Institute using a brain-dedicated PET Siemens/CT high-resolution
research tomograph (HRRT) on two consecutive days. Ab scans were acquired 40–70 min post-injec-
tion ( »6 mCi) and tau scans 80–100 min post-injection ( »10 mCi). All scans were completed
between March 2017 and April 2019.
In DIAN, PET was performed using Pittsburgh compound B ([11C]PIB) to assess Ab deposition
either with full dynamic or an acquisition 40–70 min post-injection ( »15 mCi).
Positron emission tomography processing
PREVENT-AD PET scans were processed using a standard pipeline (see https://github.com/villeneu-
velab/vlpp for more details; Bedetti, 2019). Briefly, Ab- and tau-PET images were realigned, aver-
aged, and registered to the T1-weighted scan of each participant, which had been segmented with
the Desikan–Killiany atlas using FreeSurfer version 5.3 (Desikan et al., 2006). The same structural
scan was used in the diffusion and the PET pipelines. PET images were then masked to remove the
scalp and cerebrospinal fluid to reduce contamination by non-grey and non-WM voxels. Standard-
ized uptake value ratios (SUVR) images were obtained using the whole cerebellum as reference
region for Ab-PET (Jagust et al., 2015) and the inferior cerebellar GM for tau-PET (Baker et al.,
2017). A global Ab burden was calculated from the average bilateral SUVR of medial and lateral
frontal, parietal, and temporal regions, and as described previously, participants with an average
global Ab > 1.37 SUVR were considered Ab-positive (McSweeney et al., 2020). For tau, we focused
on the average bilateral tau uptake in the entorhinal cortex as it is among the earliest cortical region
to be affected over the course of AD (Braak and Braak, 1991; Maass et al., 2017). Given that there
is no consensus yet as to how to define tau-positivity (Villemagne et al., 2021) and that the pres-
ence of Ab is needed to facilitate the accumulation of tau (Jack et al., 2019), we considered the
same proportion of Ab-positive and tau-positive participants in PREVENT-AD. As such, participants
in the top 20% of tau uptake in the entorhinal cortex were considered tau-positive. In the tau-posi-
tive group, 60% of participants were also amyloid-positive.
DIAN PET scans were processed by the DIAN image processing core and made available after
extensive quality control. Briefly, PET images were registered to the structural image that had been
processed with FreeSurfer 5.3. PET images were converted to regional SUVR using the cerebellar
GM as reference region (Su et al., 2013), and a regional spread function-based approach for partial
volume correction was applied (Su et al., 2015). A global Ab burden was calculated from averaging
the SUVR of four cortical regions (prefrontal, gyrus rectus, lateral temporal, and precuneus) typically
used in the DIAN study group (Morris et al., 2010). Participants with a global Ab SUVR above 1.42
were considered Ab-positive, as established previously (Mishra et al., 2018; Schultz et al., 2020;
Su et al., 2019).
Diffusion MRI processing
An overview of the processing steps is displayed in Figure 1.
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Preprocessing steps
The diffusion-weighted images were processed using the TractoFlow Atlas-Based Segmentation
(TractoFlow-ABS) pipeline. TractoFlow-ABS is an extension of the recent TractoFlow pipeline
(Theaud et al., 2020a) publicly available for academic research purposes (https://github.com/scilus/
tractoflow-ABS; Theaud, 2020b) that uses Nextflow (Di Tommaso et al., 2017) and Singularity
(Kurtzer et al., 2017) to ensure efficient and reproducible diffusion processing. All major processing
steps are performed through this pipeline, from preprocessing of the structural and diffusion images
to tractography. The pipeline computes typical DTI maps, fODF, and a whole-brain tractogram. The
pipeline calls different functions from various neuroimaging software, namely FSL (Jenkinson et al.,
2012), MRtrix3 (Tournier et al., 2019), ANTs (Avants et al., 2011), and DIPY (Garyfallidis et al.,
2014). For a detailed description of the different steps, see Theaud et al., 2020a.
Diffusion measures
After the preprocessing steps, different diffusion measures can be generated as part of TractoFlow-
ABS. The following DTI measures were computed using DIPY: FA, MD, RD, and AD. Along with typi-
cal DTI modeling, fODFs were also computed using constrained spherical deconvolution
(Descoteaux et al., 2007; Tournier et al., 2007) and the fiber response function from the group
average.
We also generated FW-corrected DTI measures, which were the main diffusion measures of inter-
est in this study. FW correction has been proposed as a way to remove the contamination of water
from the tissue properties by modeling the isotropic diffusion of the FW component
(Pasternak et al., 2009). FW modeling was performed using the accelerated microstructure imaging
via convex optimization (Daducci et al., 2015) to calculate FW index and FW-corrected measures,
namely FAT, MDT, ADT, and RDT. Processing was done using the freely available FreeWater pipeline
(https://github.com/scilus/freewater_flow, Bore, 2020). Removing the contribution of FW is thought
to better represent the tissue microstructure (hence the subscript T for tissue) and might be more
sensitive than the non-corrected measures (Albi et al., 2017; Chad et al., 2018; Pasternak et al.,
2012).
Tractography
The last step of the pipeline is tractography. This is where TractoFlow and TractoFlow-ABS differ.
The former uses a more sophisticated algorithm, particle filtering tractography, that takes into
account anatomical information to reduce tractography biases (Girard et al., 2014). Such an algo-
rithm requires probabilistic maps of GM, WM and cerebrospinal fluid to add additional constraints
for tracking. However, with aging, probabilistic maps in ‘bottleneck’ areas of WM fibers, for exam-
ple, where the uncinate fasciculus bends, show poorer distinction between GM and WM voxels. Fur-
thermore, increasing WM hyperintensities and general atrophy with aging also complicates the use
of more advanced algorithms. As a result, the performance of particle filtering tractography was
affected and failed to generate bundles suitable for analysis. Instead, as implemented in TractoFlow-
ABS, we opted for local tracking with a probabilistic algorithm to reconstruct whole-brain tracto-
grams. The inputs for tracking were the fODF image for directions and a WM mask for seeding. The
mask was computed by joining the WM and the subcortical masks from the structural image that
had been segmented with the Desikan–Killiany atlas in FreeSurfer version 5.3 (Desikan et al., 2006).
For tracking, seeding was initiated in voxels from the WM mask with 10 seeds per voxel. The tracto-
grams had between 2 and 3 million streamlines.
White matter bundles extraction
From the tractogram, we extracted different bundles of interest. We focused on bundles connecting
the main brain region where Ab and tau accumulate in the early phase of AD, namely the uncinate
fasciculus, the anterior cingulum, and the posterior cingulum. To extract the uncinate fasciculus and
the anterior cingulum, we used RecoBundlesX (Rheault, 2020), an automated algorithm to segment
the tractograms into different bundles. This algorithm is an improved and more stable version of
RecoBundles (Garyfallidis et al., 2018). Briefly, the method is based on shape priors to detect simi-
larity in streamlines. Taking the whole-brain tractogram and templates from the bundles of interest
as inputs, RecoBundlesX extracts bundles based on the shape of the streamlines from the templates.
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The difference between RecoBundles and RecoBundlesX resides in that the latter can take multiple
templates as inputs and multiple parameters, which refines which streamlines are included or
excluded from the final bundle. RecoBundlesX is typically run 80 times and the output is the conjunc-
tion of the multiple runs, yielding more robust bundles. RecoBundlesX does not include templates
for the posterior cingulum, and thus we used TractQuerier (Wassermann et al., 2016) for this bun-
dle. This method works with customizable queries to extract bundles based on anatomical defini-
tions. Using inclusion and exclusion regions of interest based on the FreeSurfer parcellation, we
implemented a query specifically for the posterior cingulum, as used in another recent study
(Roy et al., 2020), which can be found in Supplementary Material.
After extracting all bundles, there were inspected visually in MI-Brain (https://www.imeka.ca/fr/
mi-brain/) to make sure the shape, location, and size were adequate.
Bundle-specific quantification with tractometry
The last step required to put together the different WM measures and bundles of interest was trac-
tometry (Cousineau et al., 2017). Tractometry is a way to extract the measures of interest specifi-
cally in each bundle. It takes as input the maps of all microstructure measures and the bundles in
which we want to extract them. In our case, we extracted the average tissue measures (FAT, MDT,
RDT, ADT, and FW index) for each bundle (uncinate fasciculus, cingulum, posterior cingulum). For
complementary analyses, we also extracted typical tensor measures (average FA, MD, RD, and AD)
in each bundle. The overall approach, done entirely in native space, has the advantage of generating
bundles specific to each individual.
Statistical analysis
Partial correlations were performed to evaluate the relationships between Ab- or tau-PET and the
different microstructure measures in each bundle, controlling for age, sex, and bundle volume. In pri-
mary analyses, the diffusion measures investigated as independent variables were FAT, MDT, RDT,
ADT, and FW index. Analyses were performed separately in left and right bundles for Ab and tau.
The dependent variables were global cortical Ab and entorhinal tau SUVR. We display bivariate asso-
ciations between diffusion and PET measures to show the raw data, but we based the results on the
partial correlation coefficient of the diffusion measure, controlling for age, sex, and bundle volume
(divided by total intracranial volume). Models were first performed at the whole-group level and
then specifically in the Ab-positive or tau-positive groups versus the Ab- or tau-negative groups. We
reasoned that the participants harboring pathology (and thus being in the preclinical stage of the
disease) would be the most likely to show WM degeneration. We repeated the analyses including
either APOE e4 status or handedness as a covariate in the models. Since the results were mainly
unchanged, these data are not presented. In the bundles where associations were found between
pathology and microstructure, we further controlled for GM volume (divided by total intracranial vol-
ume) of cortical regions connected by the given bundle to evaluate whether associations were also
influenced by atrophy. For the uncinate fasciculus, GM regions of interest were the medial orbito-
frontal cortex and the parahippocampal gyrus; for the cingulum, regions were the anterior and pos-
terior cingulate; and for the posterior cingulum, regions were precuneus and parahippocampal
gyrus. We also performed similar analyses with the typical tensor measures (FA, MD, AD, and RD) to
evaluate whether the FW-corrected measures were more sensitive. Associations with a p-value < 0.05
were considered significant. Analyses were conducted using SPSS version 27 (IBM, NY, USA) and R
version 3.6.3 (R Development Core Team, 2020).
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Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. Journal of
Alzheimer’s Disease 22:909–922. DOI: https://doi.org/10.3233/JAD-2010-100678, PMID: 20858974
Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, Kim HJ, Lyoo CH, Cho H, Finsterwalder S, Duering
M, Seo SW, Ewers M, Alzheimer’s Disease Neuroimaging Initiative. 2019. Functional connectivity associated
with tau levels in ageing, alzheimer’s, and small vessel disease. Brain 142:1093–1107. DOI: https://doi.org/10.
1093/brain/awz026, PMID: 30770704
Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M, Alzheimer’s
Disease Neuroimaging Initiative (ADNI). 2020. Functional brain architecture is associated with the rate of tau
accumulation in Alzheimer’s disease. Nature Communications 11:347. DOI: https://doi.org/10.1038/s41467-
019-14159-1, PMID: 31953405
Garyfallidis E, Brett M, Amirbekian B, Rokem A, van der Walt S, Descoteaux M, Nimmo-Smith I, Dipy
Contributors. 2014. Dipy, a library for the analysis of diffusion MRI data. Frontiers in Neuroinformatics 8:8.
DOI: https://doi.org/10.3389/fninf.2014.00008, PMID: 24600385
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